派林生物(000403) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥260,860,262.39, a decrease of 47.87% compared to ¥500,420,632.99 in the same period last year[5] - Net profit attributable to shareholders was ¥56,376,087.53, down 46.62% from ¥105,604,403.84 year-on-year[5] - The net profit after deducting non-recurring gains and losses was ¥36,249,382.73, a decline of 59.73% compared to ¥90,018,691.14 in the previous year[5] - Basic earnings per share decreased to ¥0.0771, down 46.68% from ¥0.1446 year-on-year[5] - Total operating revenue for Q1 2023 was CNY 260,860,262.39, a decrease of 47.9% compared to CNY 500,420,632.99 in the same period last year[18] - The net profit for Q1 2023 was CNY 56,218,316.92, a decrease of 47.1% compared to CNY 106,003,691.20 in the same period last year[19] - Total comprehensive income for Q1 2023 was CNY 56,209,176.61, down 47.1% from CNY 106,009,588.72 in Q1 2022[19] - The total operating profit for Q1 2023 was CNY 63,173,481.12, down 47.4% from CNY 120,103,775.12 in Q1 2022[19] Cash Flow and Assets - The company's cash flow from operating activities increased by 36.56% to ¥106,564,727.56 from ¥78,037,892.32 in the same period last year[5] - Cash flow from operating activities increased to CNY 562,858,056.37, compared to CNY 475,536,500.26 in the previous year, marking a growth of 18.4%[21] - The company's cash and cash equivalents decreased to ¥973,510,301.00 from ¥1,000,797,127.67 at the beginning of the year, a decline of approximately 2.9%[14] - The cash and cash equivalents at the end of Q1 2023 amounted to CNY 973,237,430.92, a decrease from CNY 1,000,270,509.13 at the beginning of the quarter[22] - Total assets at the end of the reporting period were ¥7,925,830,728.13, a slight decrease of 0.71% from ¥7,982,324,465.77 at the end of the previous year[5] - Total current assets decreased to ¥2,985,750,503.88 from ¥3,046,975,789.60, a decline of about 2%[14] - Total liabilities decreased to CNY 1,000,750,529.04 in Q1 2023 from CNY 1,121,197,229.65 in the previous quarter, representing a reduction of 10.8%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period was 23,607[10] - The largest shareholder, Hangzhou Zhemin Investment Partnership, holds 18.35% of shares, totaling 134,464,531 shares[10] - The equity attributable to shareholders increased by 0.92% to ¥6,930,934,944.53 from ¥6,867,524,210.96 at the end of the previous year[5] - The company's equity attributable to shareholders increased to CNY 6,930,934,944.53 from CNY 6,867,524,210.96, reflecting a growth of 0.9%[16] Operational Changes - The company reported a significant increase in other income, which rose by 158.96% to ¥5,208,458.90 due to increased government subsidies[8] - The company experienced a 44.39% improvement in net cash flow from investing activities, which was -¥171,669,347.44 compared to -¥308,715,589.61 in the previous year[8] - The company reported a 175.66% increase in notes receivable, totaling ¥103,663,605.34, primarily due to an increase in commercial bills received during the period[8] - The company has announced a strategic cooperation with Xinjiang Deyuan, indicating plans for future market expansion[12] - The company is in the process of establishing an investment fund in collaboration with professional investment institutions, reflecting a new strategic direction[12] - The company has initiated a share repurchase program, demonstrating confidence in its long-term value[12] Cost and Expenses - Total operating costs for Q1 2023 were CNY 218,309,593.81, down 43.2% from CNY 384,458,625.31 year-over-year[18] - R&D expenses for Q1 2023 were CNY 14,274,385.64, slightly down from CNY 14,574,604.59 in the previous year[18] - The company incurred credit impairment losses of CNY 12,061,663.28 in Q1 2023, compared to a gain of CNY -452,725.42 in the previous year[19] Inventory and Receivables - Trade receivables decreased significantly to ¥460,878,023.27 from ¥835,877,041.68, representing a reduction of about 45%[14] - Inventory increased to ¥788,805,196.76 from ¥623,689,205.55, marking an increase of approximately 26.5%[14] - The company reported a significant increase in trading financial assets, rising to ¥495,663,687.51 from ¥422,435,301.19, an increase of approximately 17.3%[14]